Table 2.
Correlations between clinicopathological features and the number of TILs
| Parameters | TILs | p value | |
|---|---|---|---|
| High (n = 12) | Low (n = 4) | ||
| Age | |||
| ≤ 47 | 7 (58.3%) | 1 (25.0%) | |
| > 47 | 5 (41.7%) | 3 (75.0%) | 0.278 |
| Tumor size | |||
| ≤ 25 | 6 (50.0%) | 2 (50.0%) | |
| > 25 | 6 (50.0%) | 2 (50.0%) | 1.000 |
| Estrogen receptor | |||
| Negative | 7 (58.3%) | 0 (0.0%) | |
| Positive | 5 (41.7%) | 4 (100.0%) | 0.044 |
| Progesterone receptor | |||
| Negative | 9 (75.0%) | 1 (25.0%) | |
| Positive | 3 (25.0%) | 3 (75.0%) | 0.082 |
| HER2 | |||
| Negative | 4 (33.3%) | 4 (100.0%) | |
| Positive | 8 (66.7%) | 0 (0.0%) | 0.019 |
| Ki67 | |||
| Negative | 2 (16.7%) | 2 (50.0%) | |
| Positive | 10 (83.3%) | 2 (50.0%) | 0.207 |
| Intrinsic subtype HRBC | |||
| Non-HRBC | 7 (58.3%) | 0 (0.0%) | |
| HRBC | 5 (41.7%) | 4 (100.0%) | 0.044 |
| Intrinsic subtype HER2BC | |||
| Non-HER2BC | 8 (66.7%) | 4 (100.0%) | |
| HER2BC | 4 (33.3%) | 0 (0.0%) | 0.207 |
| Intrinsic subtype TNBC | |||
| Non-TNBC | 9 (75.0%) | 4 (100.0%) | |
| TNBC | 3 (25.0%) | 0 (0.0%) | 0.298 |
| Number of sentinel lymph nodes with metastasis | |||
| 1, 2 | 10 (83.3%) | 3 (75.0%) | |
| 3 | 2 (16.7%) | 1 (25.0%) | 0.734 |
| Size of sentinel lymph node itself (mm) | |||
| ≤ 12.5 | 6 (50.0%) | 2 (50.0%) | |
| > 12.5 | 6 (50.0%) | 2 (50.0%) | 1.000 |
| Size of metastatic lesion | |||
| ≤ 3400 | 5 (41.7%) | 3 (75.0%) | |
| > 3400 | 7 (58.3%) | 1 (25.0%) | 0.278 |
| Clinical response | |||
| cPR | 10 (83.3%) | 4 (100.0%) | |
| cCR | 2 (16.7%) | 0 (0.0%) | 0.417 |
| Pathological complete response | |||
| Non-pCR | 7 (58.3%) | 4 (100.0%) | |
| pCR | 5 (41.7%) | 0 (0.0%) | 0.136 |
TILs tumor-infiltrating lymphocytes, HER2 human epidermal growth factor receptor 2, HRBC hormone receptor-positive breast cancer, HER2BC HER2-enriched breast cancer, TNBC triple negative breast cancer, cPR clinical partial response, cCR clinical complete response, pCR pathological complete response